Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - A long-term clinical trial

Rhinology

Volumn 49, Issue 2, 2011, Pages 214-216

  Yaniv, Eitan ^a   Preis, Michal ^a   Shvero, Jacob ^a   Nageris, Ben ^a   Hadar, Tuvia ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epistaxis; HHT; Nasal bleeding; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPISTAXIS; FEMALE; HUMAN; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENDU OSLER WEBER DISEASE;

ADULT; EPISTAXIS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TAMOXIFEN; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 80051572751     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino09.201     Document Type: Article

References (23)

1. Hanes FM. Multiple hereditary telangiectasia causing hemorrhage (hereditary hemorrhagic telangiectasia). Bull Johns Hopkins Hosp. 1909; 20: 63-75.
2. Gibbs DD. Rendu-Osler-Weber disease: a triple eponymous title lives on. J R Soc Med. 1986; 79: 742-743.
3. Haitjema T, Westermann CJ, Overtoom TT, et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications and treatment. Arch Intern Med. 1996; 156: 714-719.
4. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Eng J Med. 1995; 333: 918-924.
5. Assar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101: 977-980.
6. Pau H, Carney AS, Walker R, et al. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol. 2000; 25: 547-550.
7. Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol. 2002; 111: 222-228.
8. Shovlin CL, Guttmacher AE, Buscanini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Gen. 2000; 91: 66-67.
9. Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope 2002; 112: 767-773.
10. Pau H, Carney AS, Murty GE. Hereditary hemorrhagic telangiectasia (Osler-Weber- Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol. 2001; 26: 93-98.
11. Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol. 2003; 36: 149-158.
12. Reilly PJ, Nostrant TT. Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 1984; 79: 363-367.
13. Shapsay SM, Oliver P. Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope 1984; 94: 1554-1556.
14. Pohar S, Mazeron JJ, Ghilezan M, et al. Management of epistaxis in Rendu-Osler disease: is brachytherapy effective? Int J Radiat Bio Phys. 1993; 27: 1073-1077.
15. Yaniv E, Preis M, Hadar T, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a double-blind placebocontrolled clinical trial. Laryngoscope 2009; 119: 284-288.
16. Al-Deen S, Bachmann-Harildstad G. A grading scale for epistaxis in hereditary haemorrhagic teleangectasia. Rhinology 2008; 46: 281-284.
17. Birch DS, Saleh HA, Wodehouse T, et al. Assessing quality of life for patients with chronic rhinosinusitis using the "Rhinosinusitis Disability Index". Rhinology 2001; 39: 191-196.
18. Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2004; 114: 750-759.
19. Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. Acta Med Scand. 1981; 209: 393-396.
20. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telengiectasia. Liver Transpl 2008; 14: 210-213.
21. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009; 360: 2143-2144.
22. Oosting S, Nagengast W, De Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009; 361: 931.
23. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006; 85: 631-632.